Print

Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/253/testing-cancer-treatments-in-recurrent-endometrial-cancer

Clinicaltrials.gov identifier:
NCT05112601 (https://clinicaltrials.gov/show/NCT05112601)

Treatment
Treatment study for people with endometrial cancer that has returned

Study Contact Information:

For additional information, please contact: the Principal Investigator: Haider S Mahdi at NRG Oncology 412-641-5609 or mahdihs@upmc.edu


About the Study

This study tests the combination of two immunotherapy drugs compared to one immunotherapy drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a biomarker known as dMMR.

What the Study Involves

This study involves 2 groups:

Study Sites

Georgia

Augusta
Augusta University Medical Center
Contact: Site Public Contact 706-721-2388 ga_cares@augusta.edu

Iowa

Iowa City
University of Iowa/Holden Comprehensive Cancer Center
Contact: Site Public Contact 800-237-1225

Missouri

Saint Louis
Washington University School of Medicine
Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu

New Mexico

Albuquerque
University of New Mexico Cancer Center
Contact: Site Public Contact 505-925-0348 HSC-ClinicalTrialInfo@salud.unm.edu

Ohio

Cleveland
Case Western Reserve University
Contact: Site Public Contact 800-641-2422 CTUReferral@UHhospitals.org

Cleveland
Cleveland Clinic Foundation
Contact: Site Public Contact 866-223-8100 TaussigReserach@ccf.org

Oklahoma

Oklahoma City
University of Oklahoma Health Sciences Center
Contact: Site Public Contact 405-271-8777 ou-clinical-trials@ouhsc.edu

Pennsylvania

Philadelphia
NRG Oncology
Contact: Haider S. Mahdi 412-641-5609 mahdihs@upmc.edu

Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Contact: Site Public Contact 412-647-8073

Rhode Island

Providence
Women and Infants Hospital
Contact: Site Public Contact 401-274-1122

Virginia

Charlottesville
University of Virginia Cancer Center
Contact: Site Public Contact 434-243-6303 uvacancertrials@hscmail.mcc.virginia.edu

Washington

Seattle
Fred Hutchinson Cancer Research Center
Contact: Site Public Contact 800-804-8824


This Study is Open To:

People 18 years or older who:

This Study is Not Open To:

People who:


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.